Chronic Myeloid Leukemia

NICE recommends first line treatment with Glivec for new CLE patients

Published in Cancer Weekly, September 23rd, 2003

The final decision issued from U.K.'s National Institute for Clinical Excellence (NICE) on the prescribing of Glivec for the treatment of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) has recommended first line treatment of patients who present in the chronic, accelerated, or blast phase of the disease.

Prior to the decision, NICE had recommended that newly diagnosed patients in the chronic phase of CML could only receive Glivec following failure or intolerance to Interferon-alpha, a less effective therapy with unpleasant side effects, which can seriously affect quality of life.

Shazia Breay, medical manager, Novartis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-09-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry